Literature DB >> 28854351

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.

Rony Dahan, Emanuela Sega, John Engelhardt, Mark Selby, Alan J Korman, Jeffrey V Ravetch.   

Abstract

Entities:  

Year:  2015        PMID： 28854351     DOI： 10.1016/j.ccell.2015.09.011

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


× No keyword cloud information.
  21 in total

1.  The PD-1 Regulatory Axis Inhibits T Cell-Independent B Cell Memory Generation and Reactivation.

Authors:  M Ariel Spurrier; Jamie E Jennings-Gee; Christina A Daly; Karen M Haas
Journal:  J Immunol       Date:  2021-09-17       Impact factor: 5.426

2.  Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events.

Authors:  Zhaoliang Huang; Xinghua Pang; Tingting Zhong; Tailong Qu; Na Chen; Shun Ma; Xinrong He; Dennis Xia; Max Wang; Michelle Xia; Baiyong Li
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

3.  Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.

Authors:  Jeremy D Waight; Dhan Chand; Sylvia Dietrich; Randi Gombos; Thomas Horn; Ana M Gonzalez; Mariana Manrique; Lukasz Swiech; Benjamin Morin; Christine Brittsan; Antoine Tanne; Belinda Akpeng; Ben A Croker; Jennifer S Buell; Robert Stein; David A Savitsky; Nicholas S Wilson
Journal:  Cancer Cell       Date:  2018-06-11       Impact factor: 31.743

4.  A Restricted Role for FcγR in the Regulation of Adaptive Immunity.

Authors:  Marieke F Fransen; Hreinn Benonisson; Wendy W van Maren; Heng Sheng Sow; Cor Breukel; Margot M Linssen; Jill W C Claassens; Conny Brouwers; Jos van der Kaa; Marcel Camps; Jan Willem Kleinovink; Kelly K Vonk; Sandra van Heiningen; Ngaisah Klar; Lianne van Beek; Vanessa van Harmelen; Lucia Daxinger; Kutty S Nandakumar; Rikard Holmdahl; Chris Coward; Qingshun Lin; Sachiko Hirose; Daniela Salvatori; Thorbald van Hall; Cees van Kooten; Piero Mastroeni; Ferry Ossendorp; J Sjef Verbeek
Journal:  J Immunol       Date:  2018-03-09       Impact factor: 5.422

5.  New tricks for old targets: Anti-CTLA-4 antibodies re-envisioned for cancer immunotherapy.

Authors:  Jeremy D Waight; Dhan Chand; David A Savitsky
Journal:  Oncotarget       Date:  2018-07-27

6.  Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.

Authors:  Itziar Ibarlucea-Benitez; Polina Weitzenfeld; Patrick Smith; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-29       Impact factor: 11.205

Review 7.  Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients.

Authors:  Sangwoo S Kim; Whitney A Sumner; Sayuri Miyauchi; Ezra E W Cohen; Joseph A Califano; Andrew B Sharabi
Journal:  Clin Cancer Res       Date:  2021-07-06       Impact factor: 12.531

Review 8.  Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors.

Authors:  Pan Shen; Liang Han; Xin Ba; Kai Qin; Shenghao Tu
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

Review 9.  Role of noninvasive molecular imaging in determining response.

Authors:  Ariel E Marciscano; Daniel L J Thorek
Journal:  Adv Radiat Oncol       Date:  2018-10-23

Review 10.  Therapy of Primary Liver Cancer.

Authors:  Mei Feng; Yisheng Pan; Ruirui Kong; Shaokun Shu
Journal:  Innovation (Camb)       Date:  2020-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.